Nicaraven Chugai.
Chugai (the Japanese subsidiary of Roche) is developing nicaraven (Antevas), a water-soluble antioxidant, for the potential treatment of disorders caused by acute cerebrovascular diseases. A registration application was filed in April 1995, and in April 2002, nicaraven was still awaiting registration in Japan. By August 2002, Chugai had filed an NDA in Japan for the additional indication of subarachnoidal bleeding.
Leker
Ronen R
RR
Laboratory of Molecular Biology, NIH/NINDS Building 36, Room 3c12, 36 Convent Drive, MSC 4092, Bethesda, MD 20892, USA. lekerr@nih.ninds.gov
D000818:Animals; D000975:Antioxidants / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001929:Brain Edema / Q000188:drug therapy; D002545:Brain Ischemia / Q000188:drug therapy; D002543:Cerebral Hemorrhage / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology* / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy; D013329:Structure-Activity Relationship
D000975:Antioxidants; D018696:Neuroprotective Agents; D009536:Niacinamide; C042625:nicaraven